When Should I Get My Second Shingles Shot?

The second dose of the recombinant shingles vaccine (Shingrix) is recommended two to six months after the first dose. That window gives the immune system enough time to build on the initial response while keeping the interval short enough to maintain strong protection. If you miss the six-month mark, you do not need to start over. Guidelines allow flexibility beyond six months, and the evidence suggests that getting the second dose late is far better than skipping it entirely.

The Standard Two-to-Six-Month Window

Shingrix was designed as a two-dose series with the second shot given two to six months after the first. This is the schedule used in the large clinical trials that demonstrated the vaccine’s effectiveness, and it is the interval recommended by the CDC and by advisory bodies in other countries. In Canada, for instance, the National Advisory Committee on Immunization endorsed the same two-to-six-month schedule when the vaccine was authorized in 2017.¹ The minimum spacing of two months is a firm floor. Getting the second shot earlier than that is not recommended because the immune response from the first dose has not had sufficient time to mature.

In practice, scheduling the second dose somewhere around the two-to-three-month mark is common because it is easy to remember and lines up well with routine pharmacy or doctor visits. There is no evidence that waiting the full six months gives you a better immune response than going at two or three months. The range exists to give people logistical flexibility, not because one end of the window is immunologically superior to the other.

What If You Miss the Six-Month Window

Life gets in the way. You might forget, get sick, run into insurance hassles, or simply not get around to it. The good news is that if you go past six months, you do not need to restart the series. Canada’s advisory committee, for example, states that a schedule stretching to twelve months may be considered when flexibility is needed to improve completion rates.¹ The CDC’s guidance in the United States is similar: if more than six months have passed, administer the second dose as soon as possible rather than restarting.

Real-world data show that many people end up getting the second shot outside the recommended window. In one large U.S. study, about 70 percent of people who received their first dose completed the series within six months, while roughly 80 percent had done so within twelve months.² That means a meaningful fraction of people are getting their second dose in the seven-to-twelve-month range, and some even later. The consistent message from public-health authorities is that however late you are, the second dose still counts and still helps.

Why the Second Dose Matters So Much

Shingrix is not like vaccines where a single dose provides years of solid protection on its own. The first shot primes the immune system, but protection from one dose alone fades substantially within a year. A real-world effectiveness study following vaccinated adults over four years found that two-dose protection held up strongly with very little waning, while one-dose protection dropped off significantly after the first year.³ The researchers underscored that this pattern highlights the importance of completing the series.

In the pivotal clinical trials, Shingrix showed greater than 90 percent efficacy against shingles and at least 89 percent efficacy against postherpetic neuralgia, the chronic nerve pain that can linger for months or years after a shingles rash clears. Those impressive numbers came from participants who received both doses. The vaccine’s protective efficacy held up well even in adults aged 70 and older, a group that typically has a weaker response to vaccines.⁴ When people talk about Shingrix being remarkably effective for a vaccine given to older adults, they are talking about the two-dose result. Skipping the second shot leaves you well short of that protection.

How Shingrix Achieves Such High Effectiveness

Part of the reason the second dose is so critical has to do with the vaccine’s design. Shingrix uses a protein from the varicella-zoster virus paired with a potent adjuvant called AS01B. The adjuvant is an ingredient added specifically to amplify the immune response, and it is what sets Shingrix apart from older approaches. Clinical trials comparing adjuvanted and unadjuvanted versions of the vaccine found that the adjuvanted formulations produced substantially higher immune responses, both in the antibodies your body makes and in the cellular immunity that helps keep the virus in check long-term.⁵

The two-dose schedule is essentially how the adjuvant strategy works best. The first dose trains the immune system to recognize the viral protein. The second dose, given weeks or months later, triggers a much stronger “booster” response that locks in long-lasting memory cells. Without that second encounter, the immune memory from a single priming dose gradually fades, which is exactly what the effectiveness data show.

Side Effects and What to Expect Before Your Second Shot

One of the most common reasons people delay or skip the second dose is the side effects from the first one. Shingrix is known for causing more noticeable reactions than many other vaccines. Soreness at the injection site is nearly universal, and many people experience fatigue, muscle aches, or headaches for a day or two. In the large clinical trials, roughly 10 percent of participants reported grade 3 reactions, meaning side effects severe enough to interfere with normal daily activities.⁴ These reactions are a direct consequence of the strong adjuvant that makes the vaccine so effective.

If you had a rough time after the first shot, the second dose tends to produce similar side effects. Some people report the second shot being slightly worse, while others find it about the same. Either way, the reactions are short-lived, typically resolving within two to three days. Scheduling the second dose before a weekend or a day off can make the experience more manageable. The side effects, while unpleasant, are a sign that your immune system is responding vigorously. Compared to the misery of a full-blown shingles episode, which can involve weeks of blistering rash and months of nerve pain, a couple of rough days is a reasonable trade-off.

Qualitative research with patients who delayed their second dose found that unpleasant or severe side effects after the first shot was a significant barrier to coming back.⁶ If the first dose hit you hard, talk to your pharmacist or doctor about timing strategies and over-the-counter pain relievers that can ease the post-vaccination window.

Who Is Less Likely to Complete the Series

Completion rates for the two-dose series are decent but far from perfect. Among adults aged 50 to 64 in the United States, about two-thirds to 70 percent received their second dose within six months, and roughly 78 to 82 percent had completed the series within a year.⁷ That still leaves a substantial minority with incomplete protection.

A study tracking more than 700,000 U.S. adults over two years found that overall adherence hovered around 72 percent at six months and climbed to about 86 percent by twenty-four months.⁸ The same study identified several factors associated with lower completion rates:

Younger age: Adults who became eligible at 50 were less likely to follow through than those in their 60s or 70s, perhaps because shingles feels like a distant threat at 50.
Race and ethnicity: Black and Hispanic adults had lower completion rates, pointing to systemic access and outreach gaps.
Income and education: Lower income and less formal education were both linked to lower adherence.
Insurance type: People with commercial insurance completed the series at lower rates than those on Medicare, possibly because Medicare Part D covers Shingrix with relatively low copays while commercial plan coverage varies.
Where the first dose was given: People who received their first dose in a pharmacy completed the series at far higher rates (74 percent) than those who received it in a medical office (48 percent), likely because pharmacies are easier to walk into without an appointment.

Cost and Insurance as Practical Barriers

Shingrix is not cheap. Without insurance, the out-of-pocket cost for each dose can run well over $100 in the United States. For people covered by Medicare Part D, the Inflation Reduction Act eliminated cost-sharing for recommended vaccines starting in 2023, which means both Shingrix doses should now be free at the point of care for Medicare beneficiaries. For people with commercial insurance, coverage varies by plan, and copays or prior authorization requirements can slow things down.

In Canada, where many provinces do not fully fund the vaccine for all eligible age groups, cost is an even more prominent barrier. Interviews with both patients and healthcare providers identified high out-of-pocket cost, inconsistent insurance coverage, and inconvenient processes for accessing the vaccine as top obstacles to completing the series.⁶ Simple forgetfulness was also a major factor on both sides of the border. Setting a phone reminder or asking the pharmacy to send a follow-up notification can help close that gap.

Getting Shingrix After a Recent Shingles Episode

If you have recently had shingles, you might wonder whether you should still get vaccinated and when. Having shingles does temporarily boost your immunity to the virus, but that natural boost fades. Vaccination is still recommended to reduce the risk of a recurrence.

The question is when to start the series. Current guidance generally suggests waiting until the acute rash has resolved and you feel recovered. A prospective study examining the timing of zoster vaccination after a shingles episode found that the immune response was similar whether the vaccine was given 6 to 12 months after the illness or more than a year later.⁹ That study was conducted with the older live vaccine, but the principle holds: your body will mount a robust response once the acute infection has cleared. Most clinicians suggest waiting at least a few months, though you should discuss the timing with your provider if you are still dealing with postherpetic neuralgia or other complications.

Can You Get Shingrix at the Same Visit as Other Vaccines

Many people eligible for Shingrix are also due for a flu shot, a COVID-19 booster, or a pneumonia vaccine. Scheduling separate visits for each of these is a hassle, so co-administration is appealing. A randomized trial evaluated giving Shingrix at the same visit as either an mRNA COVID-19 vaccine or an adjuvanted influenza vaccine. The results showed that the immune responses met the pre-set criteria for non-inferiority, meaning co-administration did not meaningfully blunt the protection from either vaccine. Safety-event rates were low across the board, though slightly higher when two vaccines were given together, topping out at about 3.3 percent for the Shingrix-plus-COVID combination compared with about 1.2 percent for the COVID vaccine alone.¹⁰

In practical terms, getting your second Shingrix dose on the same day as a flu shot or COVID booster is generally considered safe and effective. The trade-off is that side effects like arm soreness and fatigue may be more noticeable when you are getting two injections, each with its own adjuvant stimulating your immune system. If you are the type who gets hit hard by vaccine side effects, splitting the visits by a week or two is reasonable. But if convenience is the factor that will determine whether you actually show up, combining appointments is a sound strategy.

If You Previously Received the Older Shingles Vaccine

Before Shingrix became available, the only shingles vaccine in the United States was Zostavax, a live-attenuated vaccine given as a single dose. Zostavax was effective but less so than Shingrix, and its protection faded more quickly, especially in older adults. It has since been discontinued in the United States.

If you received Zostavax years ago, the CDC recommends getting the full two-dose Shingrix series. You do not get credit for the Zostavax dose. The recommended approach is to wait at least two months after your Zostavax shot before starting the Shingrix series, though most people who had Zostavax received it years ago, making the waiting period a nonissue. The second Shingrix dose then follows the same two-to-six-month schedule described above.

Reminders and Strategies That Actually Help

The research on barriers to completing the Shingrix series consistently points to the same handful of fixable problems: people forget, the cost trips them up, or the side effects from dose one scare them off. Patients who completed the series on time identified self-motivation, financial support, convenient access, and reminders as the factors that helped most.⁶

A few practical steps can make a difference. Schedule your second appointment before you leave the pharmacy after your first dose. Many pharmacies will text or call with reminders, so make sure your contact information is correct. If cost is a concern, call your insurer before the appointment to confirm coverage and any copay. For people on Medicare in the U.S., both doses should now be covered at no cost. If you are uninsured or underinsured, the manufacturer’s savings program and state-funded programs may help reduce the price. The data showing that pharmacy-based first doses lead to much higher completion rates suggest that sticking with an easily accessible pharmacy location for both doses is one of the simplest things you can do to make sure you actually follow through.

People With Weakened Immune Systems

Shingrix is not a live vaccine, which means it is safe for people with compromised immune systems, including those on immunosuppressive medications, people living with HIV, and organ-transplant recipients. This is a meaningful advantage over the older Zostavax, which was a live vaccine and therefore off-limits for immunocompromised individuals. The CDC recommends Shingrix for immunocompromised adults aged 19 and older, an earlier starting age than the general-population recommendation of 50.

The timing of the second dose for immunocompromised people follows the same two-to-six-month guideline, though some clinicians may adjust scheduling around chemotherapy cycles or transplant timelines. If you are on a medication that suppresses your immune system, your doctor may recommend getting vaccinated at a point when the suppression is at its lightest, though the vaccine can be given at any time during treatment. The immune response may be somewhat weaker in this population, but the two-dose series still provides meaningful protection against a virus that can be especially dangerous when the immune system is not at full strength.